Goldman Sachs Maintains Buy on Royalty Pharma, Raises Price Target to $51
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Chris Shibutani maintains a Buy rating on Royalty Pharma (NASDAQ:RPRX) and raises the price target from $50 to $51.
August 14, 2024 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs analyst Chris Shibutani maintains a Buy rating on Royalty Pharma and raises the price target from $50 to $51.
The Buy rating and increased price target from a reputable analyst at Goldman Sachs is likely to positively influence investor sentiment and drive short-term price appreciation for Royalty Pharma.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100